| scholarly article | Q13442814 |
| P50 | author | Elda Tagliabue | Q39272222 |
| Aline S C Fabricio | Q43258178 | ||
| Giuseppe Toffoli | Q54252459 | ||
| Anna Meneghello | Q57042707 | ||
| Federico Polo | Q61090188 | ||
| Massimo Gion | Q67526199 | ||
| Valentina Agnolon | Q89285529 | ||
| Anna Contato | Q89810499 | ||
| P2860 | cites work | Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 |
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. | Q27853194 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. | Q32033982 | ||
| Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective | Q33857362 | ||
| Receptors for epidermal growth factor and other polypeptide mitogens | Q34163558 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Multiplexed electrochemical protein detection and translation to personalized cancer diagnostics | Q34342253 | ||
| Current use of HER2 tests. | Q34346148 | ||
| Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources | Q34426178 | ||
| Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. | Q34492647 | ||
| Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 | ||
| National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers | Q34601116 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer | Q35831865 | ||
| Biotin-Streptavidin Competition Mediates Sensitive Detection of Biomolecules in Enzyme Linked Immunosorbent Assay. | Q35949209 | ||
| A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis | Q36757173 | ||
| Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. | Q38068491 | ||
| HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. | Q38453585 | ||
| HER2-Orientated Therapy in Early and Metastatic Breast Cancer | Q39147155 | ||
| Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. | Q39559611 | ||
| Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies | Q41130070 | ||
| Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. | Q41690323 | ||
| Optimization of ELISA conditions to quantify colorectal cancer antigen-antibody complex protein (GA733-FcK) expressed in transgenic plant | Q41979526 | ||
| p185 HER2/neu epitope mapping with murine monoclonal antibodies | Q42454724 | ||
| Editorial: Antibody can get it right: confronting problems of antibody specificity and irreproducibility | Q42860734 | ||
| Determining the affinity and stoichiometry of interactions between unmodified proteins in solution using Biacore | Q44156714 | ||
| The testing of endodontic materials in vitro | Q44824007 | ||
| Nutrition therapy for liver disease | Q45098253 | ||
| The Instructional Program on Drugs and Hazardous Substances in the San Francisco Unified School District, 1969–1970 | Q46002173 | ||
| Differential binding of human immunoagents and Herceptin to the ErbB2 receptor | Q47344136 | ||
| Residential instability: a perspective on system imbalance | Q47593618 | ||
| Epitope mapping by surface plasmon resonance | Q47983459 | ||
| Effectiveness of natural and synthetic blocking reagents and their application for detecting food allergens in enzyme-linked immunosorbent assays. | Q51795787 | ||
| Gastric secretion analysis--pro and contra | Q53829597 | ||
| Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays. | Q55715013 | ||
| A Reagent Resource to Identify Proteins and Peptides of Interest for the Cancer Community: Table I | Q56976246 | ||
| Optimisation and standardisation of an immunoagglutination assay for the diagnosis of Trypanosoma cruzi infection based on latex-(recombinant antigen) complexes | Q58843199 | ||
| Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae | Q67248843 | ||
| Exercise tests in cardiology. 3. Assessment of physical aptitude and work capacity | Q69664825 | ||
| The widening gap in labor relations goals | Q70052771 | ||
| Osteomas, with report of 3 cases | Q71076882 | ||
| An evaluation procedure for children 6-10 years of age | Q72271094 | ||
| Automated assay for HER-2/neu in serum | Q73406119 | ||
| Monitoring therapy by serum HER-2/neu | Q73473683 | ||
| Epitope mapping by surface plasmon resonance in the BIAcore | Q74564933 | ||
| ERBB2 oncogene in human breast cancer and its clinical significance | Q77495138 | ||
| Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value | Q83978585 | ||
| Comparative binding of disulfide-bridged PEG-Fabs | Q85002931 | ||
| Finding the right antibody for the job | Q87170262 | ||
| Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels | Q93078883 | ||
| P433 | issue | 1 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 3016 | |
| P577 | publication date | 2020-02-20 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab | |
| P478 | volume | 10 |
| Q98166392 | Graphene field-effect transistor biosensor for detection of biotin with ultrahigh sensitivity and specificity | cites work | P2860 |
Search more.